A multicentre, retrospective, cohort study evaluating association of continuous, prolonged or intermittent infusion of ceftolozane/tazobactam with probability of target attainment in patients treated for Pseudomonas aeruginosa-related infection
Latest Information Update: 30 May 2019
At a glance
- Drugs Ceftolozane/tazobactam (Primary)
- Indications Pseudomonal infections
- Focus Pharmacodynamics; Pharmacokinetics
Most Recent Events
- 30 May 2019 New trial record
- 16 Apr 2019 Results presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases